Arialys
1 known investors
Arialys Therapeutics develops precision medicines targeting pathogenic autoantibodies in the brain to treat neuropsychiatric disorders driven by autoimmune disease. The company focuses on blocking autoantibodies that target brain receptors like NMDA receptors, with initial applications in conditions including encephalitis, schizophrenia, and dementia.
BiotechDigital HealthMedical Devices
Investors · 1
In the news
- Arialys' precision therapy shows promise in rare encephalitis disorder and beyondfiercebiotech.com · 2025
- Arialys Therapeutics Raises $58M to Target Autoimmune Neuropsychiatric Diseasesgenengnews.com · 2023
- Arialys - 2025 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2023
- Arialys Therapeutics Closes $58M Seed Financingfinsmes.com · 2023
- Neuro Startup Arialys Raises $58M for Privilege of Tackling Brain Inflammation - MedCity Newsmedcitynews.com · 2023
- New startup Arialys takes aim at the immune system, hoping to create neuropsychiatry drugs | BioPharma Divebiopharmadive.com · 2023